IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.931
EU - Europa 5.945
AS - Asia 5.309
SA - Sud America 734
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 5
AN - Antartide 1
Totale 21.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.803
SG - Singapore 2.242
CN - Cina 1.683
IE - Irlanda 1.016
UA - Ucraina 910
IT - Italia 834
SE - Svezia 789
FR - Francia 705
TR - Turchia 633
GB - Regno Unito 632
BR - Brasile 618
DE - Germania 460
VN - Vietnam 268
IN - India 237
FI - Finlandia 166
RU - Federazione Russa 143
CA - Canada 67
AT - Austria 61
BE - Belgio 49
PL - Polonia 48
AR - Argentina 47
HK - Hong Kong 47
MX - Messico 41
JP - Giappone 32
BD - Bangladesh 30
CZ - Repubblica Ceca 30
ES - Italia 22
KR - Corea 19
NL - Olanda 19
ZA - Sudafrica 18
EU - Europa 17
EC - Ecuador 16
IQ - Iraq 16
CO - Colombia 12
AE - Emirati Arabi Uniti 11
EG - Egitto 11
ID - Indonesia 11
LT - Lituania 11
PK - Pakistan 11
RO - Romania 11
UZ - Uzbekistan 11
IL - Israele 9
VE - Venezuela 9
MA - Marocco 8
AL - Albania 7
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
CL - Cile 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
IR - Iran 6
KE - Kenya 6
AU - Australia 5
BO - Bolivia 5
JO - Giordania 5
SA - Arabia Saudita 5
SN - Senegal 5
CH - Svizzera 4
DK - Danimarca 4
GR - Grecia 4
LB - Libano 4
NP - Nepal 4
AZ - Azerbaigian 3
BG - Bulgaria 3
HR - Croazia 3
KG - Kirghizistan 3
MT - Malta 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
DM - Dominica 2
ET - Etiopia 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
NI - Nicaragua 2
PH - Filippine 2
QA - Qatar 2
TH - Thailandia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
HU - Ungheria 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
Totale 21.002
Salva come PNG Salva come JPEG
Città #
Singapore 1.676
Chandler 1.479
Jacksonville 1.168
Dublin 1.007
Dallas 549
Ashburn 484
Princeton 466
Beijing 452
Southend 414
Izmir 376
Nanjing 342
Los Angeles 258
Wilmington 224
The Dalles 195
Dearborn 189
Ann Arbor 177
Cambridge 174
Santa Clara 172
Altamura 167
New York 150
Boardman 148
Chieti 140
Nanchang 125
Buffalo 113
Tongling 111
Munich 103
Woodbridge 93
Houston 89
Ho Chi Minh City 80
Redondo Beach 70
Dong Ket 68
São Paulo 65
Shenyang 63
Hebei 60
Kunming 54
Tianjin 51
Brussels 47
Council Bluffs 47
Hong Kong 45
Rome 45
Vienna 45
Washington 43
Brooklyn 42
Jiaxing 40
Chicago 38
Norwalk 37
Nuremberg 37
Warsaw 36
Hanoi 35
Atlanta 32
Tokyo 31
Denver 29
London 29
Pescara 29
Stockholm 29
Montreal 28
Boston 27
Helsinki 27
Hyderabad 26
Seattle 25
Orem 24
Changsha 23
Milan 23
Brno 22
Falls Church 22
Hangzhou 20
Hefei 20
Kocaeli 19
Phoenix 19
Seoul 19
Belo Horizonte 17
Chennai 17
Poplar 17
Rio de Janeiro 17
San Francisco 17
San Mateo 17
Johannesburg 16
Lanzhou 16
Manchester 16
Mumbai 16
Toronto 16
Turku 16
Frankfurt am Main 15
Auburn Hills 14
Augusta 14
Tappahannock 14
Changchun 13
Düsseldorf 13
Guangzhou 13
Mexico City 13
Grevenbroich 12
Shanghai 12
Brasília 11
Ningbo 11
Querétaro 11
Tashkent 11
Ankara 10
Campinas 10
Da Nang 10
Edinburgh 10
Totale 13.027
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 176
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 171
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 162
90K (Mac-2 BP) in human milk 161
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 159
A multidisciplinary group for prostate cancer management: A single institution experience 159
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 158
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 148
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 147
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 144
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 142
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 142
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 141
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 137
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 137
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 135
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 134
New Targets for Therapy in Pancreatic Cancer 134
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 132
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 131
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 130
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 129
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 129
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 128
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 128
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 126
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 126
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 126
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 124
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 123
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 122
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 122
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 120
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 120
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 120
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 120
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 119
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 119
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 119
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 118
Chemotherapy preoperative for the management of breast cancer locally advanced 118
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 118
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 118
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 117
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 117
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 116
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 115
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 114
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 114
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 112
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 112
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 112
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 112
Surgical treatment of adrenal metastases from non small cell lung cancer 111
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 110
DNA ploidy and S-phase fraction in pulmonary carcinoids. 110
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 109
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 109
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 109
Tyrosine kinase inhibitors 109
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 107
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 107
Principali effetti collaterali delle terapie mediche 107
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 107
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 106
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 106
A Flow cytometric study of early gastric cancer 106
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 106
Prognostic value of 90K protein in HIV infection 105
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 105
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 105
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 104
Prognostic value of a novel circulating serum 90K antigen in breast cancer 103
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 103
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 103
Interleukin-30 Promotes Breast Cancer Growth and Progression 103
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 103
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 103
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 103
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 102
Tumor-derived microvesicles: The metastasomes. 102
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 102
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 101
Unknown primary tumors 100
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 100
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 100
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 100
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 100
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 99
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 99
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 98
Rivaroxaban for cancer-associated cardiac thrombosis 98
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 98
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 98
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 98
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 98
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 97
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 97
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 97
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 96
Totale 11.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.069
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021826 0 0 0 0 0 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/20263.947 674 378 979 925 838 153 0 0 0 0 0 0
Totale 21.851